Capsol Injection

Adult administration

As a total amino acid, administer intravenously at a maximum dosage of 1 to 1.5 g per day per kg of body weight. The infusion rate should be approximately 10 g of total amino acids over 60 minutes, with the principle of administering 30 to 40 drops per minute.

Child administration

In children, the dosage and infusion rate should be adjusted accordingly.

This medication should be used strictly according to a doctor's instructions. It should not be used in patients with hepatic coma or at risk of hepatic coma. Patients with severe renal dysfunction or elevated blood nitrogen levels should also not be administered this medication. Patients with nitrogen metabolism issues, cachexia, pulmonary edema, or very low or absent urine output should not use this medication. In cases where sodium or chloride ions are present, it should not be given to patients with hypernatremia, hyperchloremia, or alkalosis. Patients with a history of myocardial infarction or significant myocardial infarction should avoid using this medication. Caution should be taken in administering this medication to patients with severe acidosis, congestive heart failure, edema due to sodium retention, or hyperkalemia. Patients with any liver or kidney dysfunction should also use this medication carefully. This medication contains sodium bisulfite, which may cause allergic reactions or asthma attacks, so asthmatic patients should exercise particular caution. Rarely, skin rashes and other hypersensitivity reactions may occur while using this medication; in such cases, use should be immediately discontinued. Gastrointestinal symptoms such as nausea or vomiting may occasionally occur. Cardiovascular symptoms such as discomfort in the chest, palpitations, rapid pulse, and elevated blood pressure may also occur. Rapid or excessive administration of this medication can lead to metabolic acidosis. Severe symptoms such as chills, fever, headache, respiratory distress, respiratory arrest, shock, bronchospasm, and urinary tract spasms may rarely manifest. Conditions like metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, hypoglycemia, liver dysfunction, vitamin imbalance, electrolyte imbalance, and hyperammonemia in children may occur. Patients with impairment in liver or kidney function may experience elevated blood urea nitrogen levels. Patients with severely impaired liver function may present severe symptoms such as serum amino acid imbalance, metabolic alkalosis, systemic nitrogen excess, hyperammonemia, and coma. Care must be taken as excessive administration of this medication may cause electrolyte imbalances, and when used with other electrolyte solutions, careful balance must be maintained. In cases of excess usage, metabolic alkalosis may occur, particularly with formulations containing acetate ions, so caution must be observed. Patients with kidney disease, lung disease, and heart disease should adjust the dosage and rate of administration to lessen the burden of fluid overload. Diabetic patients should frequently monitor their blood glucose levels during administration of this medication. When used alongside tetracycline antibiotics, the protein-sparing effect may be diminished. Safety in pregnant women has not been established; therefore, it should only be used if the therapeutic benefits outweigh the risks. For children, due to potential immature liver function, volumes should be kept low, and blood ammonia levels should be monitored frequently. Elderly patients may have diminished physiological function, so the infusion rate should be slow, and dosage should be reduced if necessary. This medication contains electrolytes and should be closely monitored for electrolyte balance when administered in large volumes or with other electrolyte solutions. Administration should occur slowly intravenously to minimize side effects and to minimize amino acid loss to the kidneys. In colder seasons, it is advisable to warm the medication to body temperature before use. Due to the risk of infection during infusion, strict aseptic conditions must be maintained during solution preparation and management. If the solution is abnormal or not clear, it should not be used, and it must be used promptly after mixing and stored in a refrigerator for no longer than 24 hours. If crystallization occurs, it should be gently warmed and cooled to body temperature before use. When storing, soft bag products do not require venting, while vial products must be vented just before use. If the vial's protective film has been removed, it should not be used. It is essential to use this medication accurately based on the container's graduation.

Serious side effects

• Hives
• difficulty breathing
• respiratory arrest
• shock
• bronchoconstriction
• anaphylactic shock

Mild side effects

• Nausea
• vomiting
• chest discomfort
• palpitations
• rapid pulse (tachycardia)
• increased blood pressure
• metabolic acidosis
• hypophosphatemia
• alkalosis
• hyperglycemia

This medication should be kept in a sealed container to prevent exposure to air or moisture and stored at room temperature away from direct sunlight. This will help maintain the medication’s effectiveness and prevent deterioration.

Appearance

This medication is a transparent liquid filled in an injection that is colorless to pale yellow.

Package unit

250 milliliters/bottle, 500 milliliters/bottle